Glycopyrrolate Mercury Pharmaceuticals (Glycopyrronium Bromide)

Glycopyrrolate is employed in several pre‑operative and therapeutic contexts where reduction of secretions or bronchodilation is desired.

• Pre‑operative reduction of salivary, bronchial, and gastric secretions to improve airway management.
• Adjunctive treatment for peptic ulcer disease to decrease gastric acidity and protect the mucosa.
• Relief of bronchospasm in patients with chronic obstructive pulmonary disease (COPD).
• Management of excessive airway secretions in patients requiring mechanical ventilation.
• Use as an antispasmodic to relax smooth muscle in the gastrointestinal tract.

Side effects of glycopyrrolate vary in frequency and severity.

Common

• Dry mouth (xerostomia)
• Throat irritation
• Blurred vision
• Tachycardia (increased heart rate)
• Constipation
• Urinary retention

Serious

• Severe tachyarrhythmias
• Acute angle‑closure glaucoma
• Anaphylactic reactions
• Marked hypotension
• Persistent urinary retention requiring catheterisation

When prescribing glycopyrrolate, clinicians should consider several safety factors.

• Assess for a history of glaucoma, especially narrow‑angle type, before use.
• Use caution in patients with cardiovascular disease, as tachycardia may be exacerbated.
• Evaluate renal and hepatic function; dose adjustments may be needed in impairment.
• Monitor for signs of urinary retention, particularly in elderly males with prostatic hypertrophy.
• Avoid in patients with known hypersensitivity to glycopyrronium bromide or formulation excipients.
• Pregnancy category is unknown; weigh potential benefits against risks if used during pregnancy.

Glycopyrrolate may interact with other medications, influencing its safety and efficacy.

Avoid

• Other anticholinergic agents (e.g., atropine, scopolamine) that can increase anticholinergic burden.
• Sympathomimetic drugs (e.g., epinephrine) that may potentiate tachycardia.
• Monoamine oxidase inhibitors (MAOIs) when combined with certain bronchodilators.

Use with caution

• Beta‑adrenergic bronchodilators (e.g., albuterol) – monitor heart rate.
• Antihistamines with anticholinergic properties (e.g., diphenhydramine).
• Drugs affecting renal clearance, such as certain diuretics.
• Anesthetic agents that may also depress secretions; coordinate dosing.